A roundup of the latest news and updates for patients with ovarian cancer from CURE®.
There have been several updates in the field of ovarian cancer over the last several weeks. Here, CURE® looks back at some of the latest news and updates affecting patients with that cancer type.
“Our findings indicate that, despite limited evidence, opportunistic salpingectomy (surgical removal of the fallopian tubes) for ovarian cancer prevention has rapidly diffused into clinical practice in the United States,” Pritesh S. Karia said in a pre-recorded presentation of study data. “Additional studies evaluating the overall efficacy of salpingectomy are needed to support its continued use.”
Data from a case-controlled analysis of health insurance claims from a five-year period presented at the 2020 ASCO Virtual Scientific Program demonstrated that certain recurring symptoms appear to be associated with an ovarian cancer diagnosis, indicating that symptom awareness is relevant to identifying a disease that is typically diagnosed at a later stage.
The combination of mirvetuximab soravtansine and Avastin (bevacizumab) demonstrated encouraging overall response rates in patients with ovarian cancer, regardless of the disease’s previous responsiveness to platinum-based chemotherapy.
Final data from a phase 3 trial presented during the 2020 ASCO Virtual Scientific Program suggests that the combination of Lynparza (olaparib) and cediranib produce similar results to standard-of-care platinum-based chemotherapy treatments in patients with recurrent platinum-sensitive ovarian cancer.
The addition of Tecentriq (atezolizumab) to Avastin (bevacizumab), paclitaxel and carboplatin failed to meet one of the phase 3 IMagyn050 trial’s main goals of improving progression-free survival in the initial treatment of newly diagnosed, advanced-stage ovarian cancer.
